Dr. Welslau on REFLECT Interim Safety Analysis in DLBCL

Video

Manfred Welslau, MD, discusses the first interim safety analysis in treatment-naïve, CD20-positive diffuse large B-cell lymphoma following the approval of Rixathon, a Sandoz biosimilar for rituximab.

Manfred Welslau, MD, Internal Medicine, Hematology and Oncology, Onkologie Aschaffenburg, discusses the first interim safety analysis in treatment-naïve, CD20-positive diffuse large B-cell lymphoma (DLBCL) following the approval of Rixathon, a Sandoz biosimilar for rituximab (Rituxan).

The multicenter, open-label REFLECT trial recruited 80 patients 18 years or older who were eligible to receive product-label rituximab and cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP).

The primary endpoint of REFLECT is complete remission. Secondary endpoints are progression-free survival at 12 months, as well as overall survival and adverse events (AEs).

Interim baseline data and safety results were as expected. Polyneuropathy (n = 10, 12.5%), anemia (n = 8, 10%) and fatigue (n = 8, 10%) were the most commonly reported AEs. Overall, AEs were reported in 66% of patients with 24% reporting serious AEs.

The study is ongoing, but Weslau is optimistic about the totality of evidence for biosimilarity and for future biosimilar application in this space.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD